Latham & Watkins Advises on Fractyl Health’s US$60 Million Underwritten Offering of Common Stock

Fractyl Health, Inc. (Nasdaq: GUTS) (Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), has announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of US$1.00 per share. All of the securities are being offered by Fractyl. The gross proceeds from the offering to Fractyl are expected to be approximately US$60 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 29, 2025, subject to customary closing conditions.

Latham & Watkins LLP is advising the underwriters in the transaction, with a Capital Markets team led by New York partner Nathan Ajiashvili and Chicago partner Jonathan Sarna, with associates Sofia Sitterson and Emma Gilmore.